GlassScriptPhysician profile
Sapna Chaudhary
NPI 1013026186
$3,652.60
in general payments reported to CMS, 2019-2025
29 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $197 · 2021: $147 · 2022: $259 · 2023: $582 · 2024: $1,257 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $642.20 | 2019-2025 | Zepbound, Mounjaro |
| Viiv Healthcare Company | $530.74 | 2024-2025 | Apretude, Dovato |
| Abbvie INC. | $410.01 | 2020-2025 | Synthroid |
| Novo Nordisk INC | $394.86 | 2020-2025 | Ozempic, Rybelsus |
| Kaleo, INC. | $284.65 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $175.07 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $174.07 | 2019-2025 | |
| Exact Sciences Corporation | $143.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phadia US INC. | $132.63 | 2019-2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2024-2025 | Airsupra |
| Hologic Sales and Service, LLC | $88.91 | 2022-2023 | Aptima |
| Glaxosmithkline, LLC. | $72.39 | 2022-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $56.87 | 2024-2025 | Veozah |
| Sanofi Pasteur INC. | $44.66 | 2020-2022 | |
| Genentech USA, INC. | $41.11 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $39.47 | 2024 | Inspire |
| Antares Pharma, INC. | $34.47 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Cleerly, INC. | $34.03 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Linus Health, INC. | $28.55 | 2023 | |
| Vyne Pharmaceuticals INC. | $27.96 | 2020 | |
| Mayne Pharma Commercial LLC | $27.67 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.87 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.66 | 2021 | |
| Pfizer INC. | $19.49 | 2025 | |
| Galderma Laboratories, L.P. | $19.25 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.62 | 2019 | |
| Biogen, INC. | $14.34 | 2020 | |
| Daiichi Sankyo INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Chaudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.